Article Text

Download PDFPDF

EPV010/#168 Inflammatory breast cancer particularities in Tunisian patients
  1. A Zribi1,
  2. S Ben Nasr1,
  3. M Ahmad1,
  4. S Fendri2,
  5. N Mansouri1,
  6. R Arfaoui2,
  7. I Mejri1,
  8. M Balti2 and
  9. A Haddaoui2
  1. 1oncologymilitary hospital of Tunis, Oncology, Tunis, Tunisia
  2. 2military hospital of Tunis, Oncology, Tunis, Tunisia


Objectives Inflammatory breast cancer (IBC) accounts for 5 to 7% of breast cancers in Tunisia. The objective of our study was to report the therapeutic results as well as the prognostic factors of this entity.

Methods We conducted a retrospective study including patients with IBC treated in the oncology department of the military hospital of Tunis between January 2015 and December 2020

Results IBCrepresented2.7% of all BC in our population.The median age was 49 years. Invasive ductal carcinoma was reported in 98% of cases and SBR III grade in 62% of cases. Tumor was triple-negative (TN) in 22% and Her2neu overexpressed in 42% of cases.The disease wasmetastaticat diagnosis in 25% of patients. Metastasis were more frequently localized in brain(25%), liver(11%) and lungs (33%). Neoadjuvant sequential chemotherapy (CT) and mastectomy with axillary lymph nodes dissection and locoregional radiotherapy was delivered in all localized cases.Pathological complete response was noted in 29% of these cases.Patients received adjuvant Capecitabin CT in 55% of cases. Disease recurrence was observed in 66% of cases after a median time to progression of 15months.In metastatic disease,FEC orTaxanes were used as first line therapy in 90% of cases.Median overall survival was 35 months for localizedand 19 months for metastatic disease.5 years desease free survival of our study was 29%. Inpatients with metastatic disease at diagnosis, TN and HER2 overexpressed status and the presence of visceral crisis significantly impaired overall survival

Conclusions Treatment and therapeutic results remain limited in our country because of the lack of other therapeutic resources such as immunotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.